Presage Biosciences (anti-cancer drug candidate voruciclib) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Presage Biosciences (anti-cancer drug candidate voruciclib) General Information

Description

A clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor for oncology treatment. The drug has the potential to overcome mechanisms of drug resistance and significantly improve patient outcomes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 530 Fairview Avenue North
  • Suite 1000
  • Seattle, WA 98109
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 530 Fairview Avenue North
  • Suite 1000
  • Seattle, WA 98109
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Presage Biosciences (anti-cancer drug candidate voruciclib) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Presage Biosciences (anti-cancer drug candidate voruciclib)‘s full profile, request access.

Request a free trial

Presage Biosciences (anti-cancer drug candidate voruciclib) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Presage Biosciences (anti-cancer drug candidate voruciclib)‘s full profile, request access.

Request a free trial

Presage Biosciences (anti-cancer drug candidate voruciclib) FAQs

  • Where is Presage Biosciences (anti-cancer drug candidate voruciclib) headquartered?

    Presage Biosciences (anti-cancer drug candidate voruciclib) is headquartered in Seattle, WA.

  • What industry is Presage Biosciences (anti-cancer drug candidate voruciclib) in?

    Presage Biosciences (anti-cancer drug candidate voruciclib)’s primary industry is Buildings and Property.

  • Is Presage Biosciences (anti-cancer drug candidate voruciclib) a private or public company?

    Presage Biosciences (anti-cancer drug candidate voruciclib) is a Private company.

  • What is the current valuation of Presage Biosciences (anti-cancer drug candidate voruciclib)?

    The current valuation of Presage Biosciences (anti-cancer drug candidate voruciclib) is .

  • What is Presage Biosciences (anti-cancer drug candidate voruciclib)’s current revenue?

    The current revenue for Presage Biosciences (anti-cancer drug candidate voruciclib) is .

  • Who are Presage Biosciences (anti-cancer drug candidate voruciclib)’s investors?

    Presage ( Discovery Tools) has invested in Presage Biosciences (anti-cancer drug candidate voruciclib).

  • When was Presage Biosciences (anti-cancer drug candidate voruciclib) acquired?

    Presage Biosciences (anti-cancer drug candidate voruciclib) was acquired on 05-Sep-2017.

  • Who acquired Presage Biosciences (anti-cancer drug candidate voruciclib)?

    Presage Biosciences (anti-cancer drug candidate voruciclib) was acquired by Lite Strategy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process